Close Menu

personalized medicine

Scipher will use the proceeds to further commercialize PrismRA, a molecular test intended to guide treatment decisions for patients with rheumatoid arthritis.

Vikor has invested an undisclosed amount to help the startup commercialize a direct-to-consumer service that includes genomic risk testing and liquid biopsy cancer screening.

With its liquid biopsy test FDA approved and monitoring and screening offerings poised for launch, the firm is turning its attention to tumor tissue testing.

The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.

The company hopes the data will help convince clinicians to adopt the algorithm in CRC as it pushes forward validations for other areas like pancreatic and ovarian tumors.

The xT platform integrates structured clinical patient data with results from a 648-gene DNA panel and whole-transcriptome RNA sequencing.

As adoption of personalized medicines has accelerated over the last four years, so has the number of marketed genetic and exome tests.

Reveal Genomics plans to have assays available within three years, and is eager to partner with pharmaceutical and diagnostics companies to fulfill its vision.

The company is employing Guardant360 in a Phase III trial assessing the efficacy of the drug both in a larger population and in women who test positive for ESR1 mutations.

Researchers concluded that there has been significant expansion of coverage for ctDNA assays over the past four years, but policies remain very heterogeneous and often limited.

Pages